Bone protection is the single best-established benefit of hormone therapy, backed by large randomized trials and meta-analyses.

In the WHI trials, hormone therapy lowered the risk of hip fractures and total fractures and increased hip bone density compared with placebo. This is why estrogen carries an FDA-approved indication for preventing postmenopausal osteoporosis. The protection is not automatically permanent - most of the benefit fades after therapy stops, so bone health needs an ongoing plan, not a one-time decision.

What to know about this answer

This is one of the most settled areas in the whole field - trial data, meta-analyses, and every major guideline agree hormone therapy protects bone during use. The genuine disagreement is not whether it works, but how proactively it should be offered for bone alone versus reserved mainly for symptom relief.

What the research shows, and which source each finding rests on

WHI estrogen+progestogen trial: hip fracture HR 0.66 (95% CI 0.45-0.98), total fractures HR 0.76 (0.69-0.83); total hip bone density +3.7% at 3 years vs +0.14% on placebo.

B[1]

WHI estrogen-alone trial: hip fracture HR 0.61 (0.41-0.91), total fractures HR 0.70 (0.63-0.79).

B[2]

Meta-analysis of 22 RCTs found a 27% reduction in nonvertebral fractures (RR 0.73); hip and wrist fractures RR 0.60, and RR 0.45 in women under 60.

A[3]

Cochrane 2017 (22 trials, 43,637 women): fracture was the only outcome for which strong evidence showed clinical benefit from hormone therapy.

A[4]

The Menopause Society (NAMS) 2022 position: hormone therapy has been shown to prevent bone loss and fracture, and systemic estrogen carries an FDA-approved indication for prevention of postmenopausal osteoporosis.

A[5]

Fracture protection is not permanent: in WHI extended follow-up, most risks and benefits dissipated after stopping therapy.

B[6]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Offer it on bone grounds alone, not just symptoms

field clinicians in the corpus, including Dr. Kelly Casperson

Because estradiol already carries an FDA-approved indication for osteoporosis prevention, some clinicians argue a woman at meaningful fracture risk can reasonably ask for it for bone protection even without bothersome hot flashes.

A[5]

What would settle it: Nothing further is needed to establish that hormone therapy protects bone during use; what remains open is the prescribing threshold and how bone protection is maintained once therapy ends.

What is really going on here

  1. What is my bone density now, given that the fastest loss happens around the final period - and if I stop hormone therapy, what is the plan for my bones afterwards?

Questions for your doctor

  1. What is my current bone density (DEXA), and when should I get a baseline?
  2. Am I within 10 years of menopause or under 60, where the benefit-risk balance for bone protection is most favorable?
  3. If I stop hormone therapy, what is the follow-up plan for my bones?
  4. Can I ask for the DEXA's body-composition output too, not just the bone density number?

Questions with no answer yet

Since bone protection during use is well established, is there a way to maintain that protection after stopping hormone therapy without relying on another long-term medication?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Fracture protection is not permanent; in extended trial follow-up, most risks and benefits dissipated after stopping. What specifically prevents post-stopping bone loss, short of switching to another bone-active drug, has not been tested as its own research question in this population.

What would test it: A trial comparing different bone-maintenance strategies, such as staged tapering, transition to another bone agent, or lifestyle intervention alone, specifically in women stopping hormone therapy after long-term use.

Would starting hormone therapy purely for bone protection, in a woman without bothersome symptoms, still show the same fracture benefit seen in symptomatic trial populations?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The FDA-approved osteoporosis-prevention indication and the trial fracture data both come from populations that were not selected specifically for being asymptomatic. Whether the benefit is identical in a woman using hormone therapy purely for bone reasons has not been isolated as its own trial question.

What would test it: A trial or subgroup analysis specifically comparing fracture outcomes in women who start hormone therapy for bone protection alone versus those who start it primarily for symptom relief.

Sources

  1. 1.Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.Cauley JA, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density (WHI). JAMA. 2003;290(13):1729-38. · Randomised trial
  2. 2.Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.Anderson GL, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the WHI randomized controlled trial. JAMA. 2004;291(14):1701-12. · Randomised trial
  3. 3.Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials.Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA. 2001;285(22):2891-7. · Systematic review or guideline
  4. 4.Long-term hormone therapy for perimenopausal and postmenopausal women.Marjoribanks J, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;1:CD004143. · Systematic review or guideline
  5. 5.The 2022 hormone therapy position statement of The North American Menopause Society.The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. · Systematic review or guideline
  6. 6.Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.Manson JE, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the WHI randomized trials. JAMA. 2013;310(13):1353-68. · Randomised trial

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions